Among them, the compound PROTAC 29 (Table 1) showed BTK degradation ability in the human AML cell line MOLM-14 and the B-cell lymphoma cell line Ramos B cells, and this substance was reported effective when the QD was 50 mg/kg in a patient-derived xenograft mice model of mantle cell lymphoma (MCL) [60]. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.